A trio of leading institutions—Boston Children’s Hospital, Dana-Farber Cancer Institute, and Broad Clinical Labs—launched an integrated pediatric cancer genomics initiative named BrightSeq. The program combines tissue and liquid biopsy sequencing to improve genomic profiling and prognostic assessment of rare and refractory pediatric cancers. Parallel efforts focus on enhanced minimal residual disease testing by Adaptive Biotechnologies, which reported a 36% revenue increase driven by expanded clinical adoption. Meanwhile, CareDx introduced an AI-driven platform for transplant rejection diagnostics despite flat revenues in testing services, emphasizing momentum in patient and digital solutions. These initiatives collectively advance precision medicine in pediatric oncology.